GCISensyne Health launches ‘SENSE’ in partnership with Microsoft
has launched its 'SENSE' system in the UK, which was developed in partnership with Microsoft as part of an existing collaboration between the two groups.
SENSE was developed in partnership with Microsoft and the UK Clinical AI company’s health cloud technology. The technology platform is a clinical algorithm engine which generates AI algorithms (called SYNEs) for real-time decision support across multiple medical conditions.
SYNEs enable clinicians and health systems to input up-to-date information on their patients which is analysed using machine learning against the SENSE database and then used to provide reasoned advice to make clinical decisions and improve operational efficiency.
Sensyne said it has now signed its first agreement with Chelsea & Westminster Hospital NHS Foundation Trust for an algorithm produced by the SENSE system called SYNE-COV.
SYNE-COV aims to provide personalised care for COVID-19 patients by allowing clinicians to augment their clinical decisions with near real time risk prediction for three outcomes: risk of ICU admission, the need for mechanical ventilation and in-hospital mortality.
SYNE-COV was co-developed by Sensyne with critical care clinicians at Chelsea & Westminster Hospital analysing real-world evidence collected in the hospital.
Shares in Sensyne Health were trading 14.00% higher at 85.5p this morning following the announcement.
Other SYNE algorithms for different conditions are currently being developed and will be announced in due course alongside further details of SENSE’s commercial UK rollout.
Sensyne has also informed investors that it intends to launch its SENSE system and associated SYNE algorithms in the US towards the end of the current financial year.
Ultimately, the partnership with Microsoft and use of Microsoft's new health cloud technology will enable SENSE and its algorithms to be deployable globally, it noted.
“The SENSE system is a major step forward in unifying different elements of our clinical AI technology together with Microsoft's health cloud technology to deliver multiple clinical algorithms at scale,” said Lord (Paul) Drayson PhD, Chief Executive of Sensyne Health.
He added, “We are delighted to announce the first SYNE algorithm from this approach, developed in collaboration with Chelsea & Westminster NHS Foundation Trust, designed and built to help the NHS cope with a potential second wave of COVID-19."
"Chelsea and Westminster has a long tradition of innovation. It supports our key purpose to provide high quality care for patients and make the best use of resources,” said Robert Hodgkiss, Deputy Chief Executive Chelsea & Westminster Hospital NHS Foundation Trust.
He added, “We took major steps forward in our agile working during the COVID-19 pandemic and we are committed to supporting our clinicians to make crucial treatment decisions on the front line.”
For more news and updates on Sensyne Health:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.